<DOC>
	<DOCNO>NCT02444910</DOCNO>
	<brief_summary>KDT501 orally administer product design help control impair glucose insulin regulation patient insulin resistance . Nonclinical study demonstrate agonist activity KDT501 G-protein couple receptor 120 well G-protein receptor . Nonclinical study also document ability KDT501 improve insulin sensitivity glucose regulation well reduce proinflammatory signal . These property combine antihyperglycemic activity modest , partial agonist effect KDT501 peroxisome proliferator-activated receptor-gamma ( PPARγ ) receptor suggest atypical pleiotropic mechanism action KDT501 . Following provide informed consent , potential subject undergo screen procedure ensure meet inclusion exclusion criterion . Following registration study , subject undergo baseline pretreatment study , include two abdominal fat biopsy , one take cold challenge , well determination rest metabolic rate , 4 hour lipid tolerance test , 2 hour euglycemic clamp study . All pretreatment study register subject perform within 7 day prior initiate therapy . On first day treatment ( Day 0 ) , subject take first 600 mg dose KDT501 clinic , follow serum pharmacokinetic ( PK ) sample obtain every hour 6 hour dose . Subjects continue dose outpatient , 600 mg po twice daily . All dose take meal ( breakfast dinner ) . On Day 7 , subject return clinic undergo safety laboratory assessment , include PK . On Days 14 21 , subject return clinic undergo safety laboratory assessment . On Day 17 subject return clinic PK study , note . Treatment subject end Day 28 . Rapid PK assessment drug exposure , define AUC0-12h , perform follow PK sample draw Time 0 , 1h , 2h , 3h , 4h , 5h , 6h , 8h , 10h , 12h Days 7 17 . On Days 11 21 ( ±1day ) , base KDT501 drug exposure level , subject provide instruction dose adjustment KDT501 . The maximum allowed KDT501 exposure ceiling subject enrol AUC0-12h = 22,500ng-hr/mL .</brief_summary>
	<brief_title>Effects KDT501 Metabolic Features Insulin Resistant Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Written inform consent obtain prior initiation study procedures 2 . Age 4070 year 3 . Diagnosis IGT , IFG , metabolic syndrome IGT define : ) 2 hour OGTT glucose 140199mg/dL b ) fast glucose &lt; 126 mg/dL IFG define : ) 2 hour OGTT glucose &lt; 200 mg/dL b ) fast glucose 100125 mg/dL Metabolic syndrome define meet least 3 follow criterion : ) serum triglyceride &gt; 150 mg/dL ; b ) serum HDL &lt; 40 mg/dl ( male ) &lt; 50 ( female ) ; c ) BP &gt; 130/85 medical treatment ; ) waist circumference &gt; 40 '' ( male ) &gt; 35 '' ( female ) ; e ) HbA1c &gt; 5.7 % 4 . Prior therapy IGT IFG may include diet alone 5 . HbA1c &lt; 7.0 % within 28 day registration 6 . Fasting plasma glucose &lt; 126 mg/dL within 28 day registration 7 . Body mass index ( BMI ) ≥27 kg/m2 8 . Women childbearing potential negative serum pregnancy test result ≤28 day prior registration agree breastfeed investigational treatment KDT501 28 day follow final dose KDT501 . 9 . All male premenopausal female surgically sterilize agreed practice method birth control consider Investigator effective medically acceptable least 14 day prior registration , throughout treatment , 28 day follow final dose KDT501 . 10 . Adequate baseline hematologic , renal , liver function evidence laboratory test result within follow range ( obtain ≤28 day prior registration ) : Hemoglobin &gt; 11.0 gm/dL Platelet Count ≥100 x 10^3/μL White Blood Count ≥2.0 x 103/μL ≤15.0 x 103/μL Creatinine Clearance ≥60 mL/min Total Bilirubin ≤2 x upper limit normal ( ULN ) Aspartate Transferase ( AST ) ≤2.5 x ULN Alanine Transferase ( ALT ) ≤2.5 x ULN INR &lt; 1.5 PTT &lt; 1.5 ULN 11 . World Health Organization ( WHO ) performance status 01 1 . Prior current history T2DM 2 . Type 1 diabetes 3 . Subjects IGT IFG hypoglycemic unawareness and/or recurrent severe hypoglycemia 4 . NYHA CHF Class 24 5 . Any significant , active pulmonary disorder include FEV1 &lt; 60 % predict base outpatient spirometry 6 . History significant cardiovascular disease , include arrhythmia , clinically significant ECG abnormality , uncontrolled hypertension , myocardial infarction unstable angina pectoris within past 6 month 7 . History HIV AIDS 8 . Active Hepatitis B C infection require therapy within past 6 month 9 . History significant , active gastrointestinal disorder , include GERD &gt; grade 2 severity 10 . History gastrectomy GI tract surgery may affect digestion absorption 11 . Positive fecal occult blood 12 . Concomitant therapy anticoagulant , aspirin aspirin containing product . Low dose aspirin ( ≤81 mg qd ) allow PT/INR aPTT value WNL . 13 . Any significant , active hematological disorder 14 . Concomitant therapy CYP2C9 substrates inhibitor 15 . Any major surgery ( e.g. , surgery require general anesthesia ) ≤28 day prior registration 16 . Systemic treatment investigational clinical trial ≤28 day prior registration 17 . Systemic glucocorticoid immunosuppressive therapy use ≤28 day prior registration . Use short course ( i.e. , ≤1 day ) glucocorticoid acceptable prevent reaction IV contrast use CT scan . Topical inhale steroid medication allow . 18 . Any infection require parenteral antibiotic therapy cause fever ( i.e. , temperature &gt; 100.5°F &gt; 38.1°C ) ≤7 day prior registration 19 . A contraindication use KDT501 20 . Any medical intervention , condition , circumstance , opinion Investigator KinDex Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>KDT501</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Type 2</keyword>
	<keyword>KinDex</keyword>
</DOC>